(secondQuint)Rabeprazole Extended-Release 50 mg vs.

 Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD).

 This is a multicenter, randomized, double-blind, double-dummy, parallel-group study.

 Subjects who meet all eligibility criteria will be randomly assigned to 1 of 2 treatment groups, RAB ER 50 mg (once daily) or Ranitidine 150 mg (twice daily).

.

 Rabeprazole Extended-Release 50 mg vs.

 Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)@highlight

The purpose of this study is to compare the efficacy of rabeprazole extended release (ER) 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive gastroesophageal reflux disease (eGERD).

